Table 4.
Multivariate analysis of LRFS on quality of life of QLQ-C30 among 501 patients with nasopharyngeal carcinoma
| HR | 95%CI | P | |
|---|---|---|---|
| Age | 1.583 | 0.582–4.302 | 0.368 |
| Gender | 1.017 | 0.300–3.450 | 0.978 |
| Marriage | 0.479 | 0.099–2.320 | 0.360 |
| Education | 1.337 | 0.852–2.098 | 0.206 |
| Smoking history | 1.455 | 0.512–4.139 | 0.482 |
| Alcohol history | 1.086 | 0.480–2.458 | 0.843 |
| T stage | 1.267 | 0.361–4.449 | 0.712 |
| N stage | 1.604 | 0.616–4.172 | 0.333 |
| Pre-treatment EBV DNA | 1.221 | 0.491–3.035 | 0.667 |
| Post-treatment EBV DNA | 3.093 | 0.881–10.857 | 0.078 |
| Cognitive functioning | 0.971 | 0.951–0.990 | 0.004 |
Abbreviations: LRFS Loco regional recurrent free survival, HR Harsard ratio